Skip to main content
. Author manuscript; available in PMC: 2020 Jul 28.
Published in final edited form as: J Gene Med. 2009 Jul;11(7):570–579. doi: 10.1002/jgm.1332

Figure 5.

Figure 5.

Challenge with recombinant vaccinia virus. Protection against challenge with HIV gp160-expressing vaccinia virus (vPE16) was examined 15 weeks after the immunization. Three days after challenge, vaccinia virus titers were examined in mouse ovaries using a plaque assay (left panel) or β-galactosidase assay (right panel)